Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADP062
- Development stage
- Preclinical
- Lead developer
- Alector
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
ADP062 is an investigational small interfering RNA (siRNA) therapeutic being developed by Alector. It is designed to target and reduce the expression of alpha-synuclein (α-Syn), a protein that abnormally aggregates in the brains of patients with synucleinopathies, including Parkinson's disease, Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB). By utilizing the RNA interference (RNAi) pathway, ADP062 aims to lower the production of α-Syn at the genetic level by degrading its messenger RNA (mRNA), potentially slowing or halting the progression of neurodegeneration associated with toxic protein accumulation.
02
Targets
SNCA (Alpha-synuclein)
Beyond the preview
Go deeper on ADP062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADP062.